バージニアにおける喉頭がんの臨床試験
バージニア内の拠点で、喉頭がんに関する7件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06589804Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06980038BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他6件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06532279SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。